6. Enfermedad por hígado graso no  alcohólico y opciones de tratamiento  con análogos de receptor de GLP-1

Alejandro Ramos Sánchez

Alejandro Ramos Sánchez Medicina Interna Hospital. Universitario San Francisco de Anís

Palabras clave: Hígado graso, Análogos receptor GLP-1

Abstract

Se presenta una revisión del estado actual de conocimiento sobre la enfermedad por hígado graso no alcohólica y los estudios realizados con análogos de GLP-1 para su prevención y tratamiento. También se incide en la conveniencia de reconocer a los pacientes predispuestos a padecerla para realizar el cribado de la enfermedad y valorar el riesgo de progresión a cirrosis y sus complicaciones.

A review of the current state of knowledge on non-alcoholic fatty liver disease and the studies carried out with GLP-1 analogues for its prevention and treatment are presented. It also emphasizes the convenience of paying more attention to patients predisposed to suffering from it to carry out adequate screening of the disease, the risk of progression to cirrhosis and its complications.

Recibido: 06 Abril 2023
Revisión: 11 Abril 2023
Aceptado: 05 Mayo 2023

Citas

Vol. 75. N2; págs. 284-291. 2021. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. Doi: 10.1016/j.jhep.2021.02.034.

Vol. 64. N6; págs. 1388-1402. 2016. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol.

Vol 67. N1; págs. 328-357. 2018. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology.

Vol 31. N6; págs. 364-366. 2020. Cusi K, Godinez Leiva E. Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. Curr Opin Lipidol.

Vol 8. N2; págs 215-221. 2020. Gadiparthi C, Spatz M, Greenberg S, et al. NAFLD epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States. J Clin Transl Hepatol.

Vol. 161. N5; págs:1657-1669. 2021. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology Doi:. 10.1053/j.gastro.2021.07.049.

Vol. 387. N10019. Págs. 679-690. 2016. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. Doi: 10.1016/S0140-6736(15)00803.

Vol 384. N12. Págs.. 1113-1124. 2020. Newsome PN, Buchholtz K, Cusi K, et al.; A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. Doi: 10.1056/NEJMoa2028395

Vol 35. N10. Págs. 1434-1439. 2018. Cusi K, Sattar N, García-Pérez LE, et al. Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabetic Medicine. Doi: https://doi.org/10.1111/dme.13697

Vol 398. N10295. Págs. 143-155. 2021. Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial. The Lancet. Doi: https://doi.org/10.1016/S0140-6736(21)01324-6

Vol 385. N6. Págs. 503-515. 2021. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa2107519

Vol 398. N10300. Págs. 583-598. 2021. Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial. The Lancet. Doi: https://doi.org/10.1016/s0140-6736(21)01443-4

Vol 44. N2. Págs 399-406. 2021. Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. Doi: https://doi.org/10.2337%2Fdc20-1997